Compare IMMP & MSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMP | MSB |
|---|---|---|
| Founded | 1987 | 1961 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.7M | 418.0M |
| IPO Year | 2012 | 1995 |
| Metric | IMMP | MSB |
|---|---|---|
| Price | $2.65 | $31.15 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 150.3K | 34.8K |
| Earning Date | 01-01-0001 | 04-17-2026 |
| Dividend Yield | N/A | ★ 4.21% |
| EPS Growth | N/A | ★ 391.29 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $98,595,651.00 |
| Revenue This Year | $372.23 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $35.81 |
| Revenue Growth | N/A | ★ 331.26 |
| 52 Week Low | $1.32 | $22.55 |
| 52 Week High | $3.53 | $42.38 |
| Indicator | IMMP | MSB |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 35.84 |
| Support Level | $2.56 | $29.75 |
| Resistance Level | $2.71 | $32.64 |
| Average True Range (ATR) | 0.13 | 1.33 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 11.59 | 16.83 |
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.